메뉴 건너뛰기




Volumn 12, Issue 11, 2014, Pages 1021-1027

Myeloid-derived suppressor cells in malignant melanoma;Myeloide Suppressorzellen (MDSC) beim malignen Melanom

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOMODULATING AGENT; CYTOKINE;

EID: 84911375802     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/ddg.12411     Document Type: Review
Times cited : (60)

References (50)
  • 1
  • 2
    • 84893339764 scopus 로고    scopus 로고
    • Malignant melanoma S3-guideline "diagnosis, therapy and follow-up of melanoma
    • Pflugfelder A, Kochs C, Blum A, et al. Malignant melanoma S3-guideline "diagnosis, therapy and follow-up of melanoma ". J Dtsch Dermatol Ges 2013; Suppl 6: 1-116.
    • (2013) J Dtsch Dermatol Ges , pp. 1-116
    • Pflugfelder, A.1    Kochs, C.2    Blum, A.3
  • 3
    • 33746562357 scopus 로고    scopus 로고
    • Immunotherapy of malignant melanoma - Basic principles and novel therapeutic approaches
    • Enk AH, Becker JC, Schuler G,. Immunotherapy of malignant melanoma-basic principles and novel therapeutic approaches. J Dtsch Dermatol Ges 2006; 4: 635-45.
    • (2006) J Dtsch Dermatol Ges , vol.4 , pp. 635-645
    • Enk, A.H.1    Becker, J.C.2    Schuler, G.3
  • 4
    • 33847615238 scopus 로고    scopus 로고
    • Dendritic cell-based immunotherapy of malignant melanoma: Success and limitations
    • Tuettenberg A, Schmitt E, Knop J, Jonuleit H,. Dendritic cell-based immunotherapy of malignant melanoma: success and limitations. J Dtsch Dermatol Ges 2007; 5: 190-6.
    • (2007) J Dtsch Dermatol Ges , vol.5 , pp. 190-196
    • Tuettenberg, A.1    Schmitt, E.2    Knop, J.3    Jonuleit, H.4
  • 5
    • 20944442315 scopus 로고    scopus 로고
    • Escape strategies and reasons for failure in the interaction between tumour cells and the immune system: How can we tilt the balance towards immune-mediated cancer control
    • Rivoltini L, Canese P, Huber V, et al. Escape strategies and reasons for failure in the interaction between tumour cells and the immune system: how can we tilt the balance towards immune-mediated cancer control ? Expert Opin Biol Ther 2005; 5: 463-76.
    • (2005) Expert Opin Biol Ther , vol.5 , pp. 463-476
    • Rivoltini, L.1    Canese, P.2    Huber, V.3
  • 6
    • 33745365936 scopus 로고    scopus 로고
    • Tumor-stroma interactions: Their role in the control of tumor cell invasion and metastasis
    • Löffek S, Zigrino P, Mauch C,. Tumor-stroma interactions: their role in the control of tumor cell invasion and metastasis. J Dtsch Dermatol Ges 2006; 4: 496-502.
    • (2006) J Dtsch Dermatol Ges , vol.4 , pp. 496-502
    • Löffek, S.1    Zigrino, P.2    Mauch, C.3
  • 7
    • 84856727864 scopus 로고    scopus 로고
    • Novel insights into the molecular mechanisms of HLA class i abnormalities
    • Seliger B,. Novel insights into the molecular mechanisms of HLA class I abnormalities. Cancer Immunol Immunother 2012; 61: 249-54.
    • (2012) Cancer Immunol Immunother , vol.61 , pp. 249-254
    • Seliger, B.1
  • 8
    • 34848819211 scopus 로고    scopus 로고
    • Failure at the effector phase: Immune barriers at the level of the melanoma tumor microenvironment
    • Gajewski TF,. Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment. Clin Cancer Res 2007; 13: 5256-61.
    • (2007) Clin Cancer Res , vol.13 , pp. 5256-5261
    • Gajewski, T.F.1
  • 9
    • 48349102876 scopus 로고    scopus 로고
    • Macrophage polarization in tumour progression
    • Sica A, Larghi P, Mancino A, et al. Macrophage polarization in tumour progression. Semin Cancer Biol 2008; 18: 349-55.
    • (2008) Semin Cancer Biol , vol.18 , pp. 349-355
    • Sica, A.1    Larghi, P.2    Mancino, A.3
  • 10
    • 79957834585 scopus 로고    scopus 로고
    • Regulatory dendritic cells: New targets for cancer immunotherapy
    • Shurin MR, Naiditch H, Zhong H, Shurin GV,. Regulatory dendritic cells: new targets for cancer immunotherapy. Cancer Biol Ther 2011; 11: 988-92.
    • (2011) Cancer Biol Ther , vol.11 , pp. 988-992
    • Shurin, M.R.1    Naiditch, H.2    Zhong, H.3    Shurin, G.V.4
  • 12
    • 84862153001 scopus 로고    scopus 로고
    • New insights into chronic inflammation-induced immunosuppression
    • Kanterman J, Sade-Feldman M, Baniyash M,. New insights into chronic inflammation-induced immunosuppression. Semin Cancer Biol 2012; 22: 307-18.
    • (2012) Semin Cancer Biol , vol.22 , pp. 307-318
    • Kanterman, J.1    Sade-Feldman, M.2    Baniyash, M.3
  • 13
    • 84862143053 scopus 로고    scopus 로고
    • Melanoma-induced immunosuppression and its neutralization
    • Umansky V, Sevko A,. Melanoma-induced immunosuppression and its neutralization. Semin Cancer Biol 2012; 22: 319-26.
    • (2012) Semin Cancer Biol , vol.22 , pp. 319-326
    • Umansky, V.1    Sevko, A.2
  • 14
    • 77955549860 scopus 로고    scopus 로고
    • Myeloid-derived suppressor cells: More mechanisms for inhibiting antitumor immunity
    • Ostrand-Rosenberg S,. Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol Immunother 2010; 59: 1593-600.
    • (2010) Cancer Immunol Immunother , vol.59 , pp. 1593-1600
    • Ostrand-Rosenberg, S.1
  • 15
    • 77951258918 scopus 로고    scopus 로고
    • Myeloid-derived suppressor cell heterogeneity and subset definition
    • Peranzoni E, Zilio S, Marigo I, et al. Myeloid-derived suppressor cell heterogeneity and subset definition. Curr Opin Immunol 2010; 22: 238-44.
    • (2010) Curr Opin Immunol , vol.22 , pp. 238-244
    • Peranzoni, E.1    Zilio, S.2    Marigo, I.3
  • 16
    • 84856706929 scopus 로고    scopus 로고
    • Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients
    • Filipazzi P, Huber V, Rivoltini L,. Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients. Cancer Immunol Immunother 2012; 61: 255-63.
    • (2012) Cancer Immunol Immunother , vol.61 , pp. 255-263
    • Filipazzi, P.1    Huber, V.2    Rivoltini, L.3
  • 17
    • 84864474722 scopus 로고    scopus 로고
    • On the armament and appearances of human myeloid-derived suppressor cells
    • Poschke I, Kiessling R,. On the armament and appearances of human myeloid-derived suppressor cells. Clin Immunol 2012; 144: 250-68.
    • (2012) Clin Immunol , vol.144 , pp. 250-268
    • Poschke, I.1    Kiessling, R.2
  • 18
    • 75149179545 scopus 로고    scopus 로고
    • Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer
    • Pan PY, Ma G, Weber KJ, et al. Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer. Cancer Res 2010; 70: 99-108.
    • (2010) Cancer Res , vol.70 , pp. 99-108
    • Pan, P.Y.1    Ma, G.2    Weber, K.J.3
  • 19
    • 79952281184 scopus 로고    scopus 로고
    • Angiogenesis and immunity: A bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy
    • Tartour E, Pere H, Maillere B, et al. Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy. Cancer Metastasis Rev 2011; 30: 83-95.
    • (2011) Cancer Metastasis Rev , vol.30 , pp. 83-95
    • Tartour, E.1    Pere, H.2    Maillere, B.3
  • 20
    • 80054730389 scopus 로고    scopus 로고
    • Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model
    • Meyer C, Sevko A, Ramacher M, et al. Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model. PNAS U S A 2011; 108: 17111-6.
    • (2011) PNAS U S A , vol.108 , pp. 17111-17116
    • Meyer, C.1    Sevko, A.2    Ramacher, M.3
  • 21
    • 84875511757 scopus 로고    scopus 로고
    • Tumor necrosis factor-alpha blocks differentiation and enhances suppressive activity of immature myeloid cells during chronic inflammation
    • Sade-Feldman M, Kanterman J, Ish-Shalom E,. Tumor necrosis factor-alpha blocks differentiation and enhances suppressive activity of immature myeloid cells during chronic inflammation. Immunity 2013; 38: 541-54.
    • (2013) Immunity , vol.38 , pp. 541-554
    • Sade-Feldman, M.1    Kanterman, J.2    Ish-Shalom, E.3
  • 22
    • 77950346282 scopus 로고    scopus 로고
    • Immunity, inflammation, and cancer
    • Grivennikov SI, Greten FR, Karin M,. Immunity, inflammation, and cancer. Cell 2010; 140: 883-99.
    • (2010) Cell , vol.140 , pp. 883-899
    • Grivennikov, S.I.1    Greten, F.R.2    Karin, M.3
  • 23
    • 60749122560 scopus 로고    scopus 로고
    • Melanoma and innate immunity - Active inflammation or just erroneous attraction?: Melanoma as the source of leukocyte-attracting chemokines
    • Navarini-Meury AA, Conrad C,. Melanoma and innate immunity-Active inflammation or just erroneous attraction?: Melanoma as the source of leukocyte-attracting chemokines. Semin Cancer Biol 2009; 19: 84-91.
    • (2009) Semin Cancer Biol , vol.19 , pp. 84-91
    • Navarini-Meury, A.A.1    Conrad, C.2
  • 24
    • 70350558753 scopus 로고    scopus 로고
    • Physiology and therapeutics of vascular endothelial growth factor in tumor immunosuppression
    • Johnson B, Osada T, Clay T,. Physiology and therapeutics of vascular endothelial growth factor in tumor immunosuppression. Curr Mol Med 2009; 9: 702-7.
    • (2009) Curr Mol Med , vol.9 , pp. 702-707
    • Johnson, B.1    Osada, T.2    Clay, T.3
  • 25
    • 78650756969 scopus 로고    scopus 로고
    • Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function
    • Condamine T, Gabrilovich DI,. Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol 2011; 32: 19-25.
    • (2011) Trends Immunol , vol.32 , pp. 19-25
    • Condamine, T.1    Gabrilovich, D.I.2
  • 26
    • 70350500225 scopus 로고    scopus 로고
    • STATs in cancer inflammation and immunity: A leading role for STAT3
    • Yu H, Pardoll D, Jove R,. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009; 9: 798-809.
    • (2009) Nat Rev Cancer , vol.9 , pp. 798-809
    • Yu, H.1    Pardoll, D.2    Jove, R.3
  • 27
    • 84897029294 scopus 로고    scopus 로고
    • Exosomes from RBC units bind to monocytes and induce pro-inflammatory cytokines, boosting T cell responses in vitro
    • Danesh A, Inglis HC, Jackman RP,. Exosomes from RBC units bind to monocytes and induce pro-inflammatory cytokines, boosting T cell responses in vitro. Blood 2014; 123: 687-96.
    • (2014) Blood , vol.123 , pp. 687-696
    • Danesh, A.1    Inglis, H.C.2    Jackman, R.P.3
  • 28
    • 0032560475 scopus 로고    scopus 로고
    • Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice
    • Kaplan DH, Shankaran V, Dighe AS,. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A 1998; 95: 7556-61.
    • (1998) Proc Natl Acad Sci U S A , vol.95 , pp. 7556-7561
    • Kaplan, D.H.1    Shankaran, V.2    Dighe, A.S.3
  • 29
    • 80053469514 scopus 로고    scopus 로고
    • The two faces of interferon-Î in cancer
    • Zaidi MR, Merlino G,. The two faces of interferon-Î in cancer. Clin Cancer Res 2011; 17: 6118-24.
    • (2011) Clin Cancer Res , vol.17 , pp. 6118-6124
    • Zaidi, M.R.1    Merlino, G.2
  • 30
    • 33749488765 scopus 로고    scopus 로고
    • Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytes
    • Valenti R, Huber V, Filipazzi P, et al. Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytes. Cancer Res 2006; 66: 9290-8.
    • (2006) Cancer Res , vol.66 , pp. 9290-9298
    • Valenti, R.1    Huber, V.2    Filipazzi, P.3
  • 31
    • 56449092100 scopus 로고    scopus 로고
    • Melanoma-specific memory T cells are functionally active in Ret transgenic mice without macroscopic tumors
    • Umansky V, Abschuetz O, Osen W, et al. Melanoma-specific memory T cells are functionally active in Ret transgenic mice without macroscopic tumors. Cancer Res 2008; 68: 9451-8.
    • (2008) Cancer Res , vol.68 , pp. 9451-9458
    • Umansky, V.1    Abschuetz, O.2    Osen, W.3
  • 32
    • 67650354587 scopus 로고    scopus 로고
    • Activation of p38 mitogen-activated protein kinase drives dendritic cells to become tolerogenic in ret transgenic mice spontaneously developing melanoma
    • Zhao F, Falk C, Osen W,. Activation of p38 mitogen-activated protein kinase drives dendritic cells to become tolerogenic in ret transgenic mice spontaneously developing melanoma. Clin Cancer Res 2009; 15: 4382-90.
    • (2009) Clin Cancer Res , vol.15 , pp. 4382-4390
    • Zhao, F.1    Falk, C.2    Osen, W.3
  • 33
    • 77954226431 scopus 로고    scopus 로고
    • Skin melanoma development in ret transgenic mice despite the depletion of CD25+Foxp3+ regulatory T cells in lymphoid organs
    • Kimpfler S, Sevko A, Ring S, et al. Skin melanoma development in ret transgenic mice despite the depletion of CD25+Foxp3+ regulatory T cells in lymphoid organs. J Immunol 2009; 183: 6330-7.
    • (2009) J Immunol , vol.183 , pp. 6330-6337
    • Kimpfler, S.1    Sevko, A.2    Ring, S.3
  • 34
    • 77953141534 scopus 로고    scopus 로고
    • Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign
    • Poschke I, Mougiakakos D, Hansson J,. Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res 2010; 70: 4335-45.
    • (2010) Cancer Res , vol.70 , pp. 4335-4345
    • Poschke, I.1    Mougiakakos, D.2    Hansson, J.3
  • 35
    • 84880294344 scopus 로고    scopus 로고
    • Vemurafenib reverses immunosuppression by myeloid derived suppressor cells
    • Schilling B, Sucker A, Griewank K, et al. Vemurafenib reverses immunosuppression by myeloid derived suppressor cells. Int J Cancer 2013; 133: 1653-63.
    • (2013) Int J Cancer , vol.133 , pp. 1653-1663
    • Schilling, B.1    Sucker, A.2    Griewank, K.3
  • 36
    • 84896523495 scopus 로고    scopus 로고
    • Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: Comparison with regulatory T cells and NY-ESO-1- or melan-A-specific T cells
    • Weide B, Martens A, Zelba H, et al. Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: comparison with regulatory T cells and NY-ESO-1- or melan-A-specific T cells. Clin Cancer Res 2014; 20: 1601-9.
    • (2014) Clin Cancer Res , vol.20 , pp. 1601-1609
    • Weide, B.1    Martens, A.2    Zelba, H.3
  • 37
    • 84896523643 scopus 로고    scopus 로고
    • Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid-derived suppressor cells as well as their Arginase 1 production
    • de Coana YP, Poschke I, Gentlcore G, et al. Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid-derived suppressor cells as well as their Arginase 1 production. Cancer Immunol Res 2013; 1: 158-62.
    • (2013) Cancer Immunol Res , vol.1 , pp. 158-162
    • De Coana, Y.P.1    Poschke, I.2    Gentlcore, G.3
  • 38
    • 78649674576 scopus 로고    scopus 로고
    • Targeting immune suppressing myeloid-derived suppressor cells in oncology
    • Kao J, Ko EC, Eisenstein S,. Targeting immune suppressing myeloid-derived suppressor cells in oncology. Crit Rev Oncol Hematol 2011; 77: 12-9.
    • (2011) Crit Rev Oncol Hematol , vol.77 , pp. 12-19
    • Kao, J.1    Ko, E.C.2    Eisenstein, S.3
  • 39
    • 38049181485 scopus 로고    scopus 로고
    • Reversion of immune tolerance in advanced malignancy: Modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function
    • Pan PY, Wang GX, Yin B, et al. Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function. Blood 2008; 111: 219-28.
    • (2008) Blood , vol.111 , pp. 219-228
    • Pan, P.Y.1    Wang, G.X.2    Yin, B.3
  • 40
    • 65549141834 scopus 로고    scopus 로고
    • The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies
    • Ozao-Choy J, Ma G, Kao J, et al. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res 2009; 69: 2514-22.
    • (2009) Cancer Res , vol.69 , pp. 2514-2522
    • Ozao-Choy, J.1    Ma, G.2    Kao, J.3
  • 41
    • 33749461167 scopus 로고    scopus 로고
    • All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients
    • Mirza N, Fishman M, Fricke I, et al. All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res 2006; 66: 9299-307.
    • (2006) Cancer Res , vol.66 , pp. 9299-9307
    • Mirza, N.1    Fishman, M.2    Fricke, I.3
  • 42
    • 58549103730 scopus 로고    scopus 로고
    • Combination of all-trans retinoic acid and a human papillomavirus therapeutic vaccine suppresses the number and function of immature myeloid cells and enhances antitumor immunity
    • Song X, Ye D, Liu B, et al. Combination of all-trans retinoic acid and a human papillomavirus therapeutic vaccine suppresses the number and function of immature myeloid cells and enhances antitumor immunity. Cancer Sci 2009; 100: 334-40.
    • (2009) Cancer Sci , vol.100 , pp. 334-340
    • Song, X.1    Ye, D.2    Liu, B.3
  • 43
    • 84862120892 scopus 로고    scopus 로고
    • Paclitaxel promotes differentiation of myeloid-derived suppressor cells into dendritic cells in vitro in a TLR4-independent manner
    • Michels T, Shurin GV, Naiditch H,. Paclitaxel promotes differentiation of myeloid-derived suppressor cells into dendritic cells in vitro in a TLR4-independent manner. J Immunotoxicol 2012; 9: 292-300.
    • (2012) J Immunotoxicol , vol.9 , pp. 292-300
    • Michels, T.1    Shurin, G.V.2    Naiditch, H.3
  • 44
    • 84860518841 scopus 로고    scopus 로고
    • Application of paclitaxel in low non-cytotoxic doses supports vaccination with melanoma antigens in normal mice
    • Sevko A, Kremer V, Falk C, et al. Application of paclitaxel in low non-cytotoxic doses supports vaccination with melanoma antigens in normal mice. J Immunotoxicol 2012; 9: 275-81.
    • (2012) J Immunotoxicol , vol.9 , pp. 275-281
    • Sevko, A.1    Kremer, V.2    Falk, C.3
  • 45
    • 84874232680 scopus 로고    scopus 로고
    • Antitumor effect of paclitaxel is mediated by inhibition of myeloid-derived suppressor cells and chronic inflammation in the spontaneous melanoma model
    • Sevko A, Michels T, Vrohlings M, et al. Antitumor effect of paclitaxel is mediated by inhibition of myeloid-derived suppressor cells and chronic inflammation in the spontaneous melanoma model. J Immunol 2013; 190: 2464-71.
    • (2013) J Immunol , vol.190 , pp. 2464-2471
    • Sevko, A.1    Michels, T.2    Vrohlings, M.3
  • 46
    • 25144466458 scopus 로고    scopus 로고
    • Gemcitabine selectively eliminates splenic Gr-1+/CD11b +myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity
    • Suzuki E, Kapoor V, Jassar AS,. Gemcitabine selectively eliminates splenic Gr-1+/CD11b +myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res 2005; 11: 6713-21.
    • (2005) Clin Cancer Res , vol.11 , pp. 6713-6721
    • Suzuki, E.1    Kapoor, V.2    Jassar, A.S.3
  • 47
    • 77951086882 scopus 로고    scopus 로고
    • 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity
    • Vincent J, Mignot G, Chalmin F, et al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res 2010; 70: 3052-61.
    • (2010) Cancer Res , vol.70 , pp. 3052-3061
    • Vincent, J.1    Mignot, G.2    Chalmin, F.3
  • 48
    • 79954471164 scopus 로고    scopus 로고
    • Rgs2 mediates pro-angiogenic function of myeloid derived suppressor cells in the tumor microenvironment via upregulation of MCP-1
    • Boelte KC, Gordy LE, Joyce S,. Rgs2 mediates pro-angiogenic function of myeloid derived suppressor cells in the tumor microenvironment via upregulation of MCP-1. PLoS One 2011; 6: e18534.
    • (2011) PLoS One , vol.6 , pp. e18534
    • Boelte, K.C.1    Gordy, L.E.2    Joyce, S.3
  • 49
    • 33751531874 scopus 로고    scopus 로고
    • Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function
    • Serafini P, Meckel K, Kelso M,. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med 2006; 203: 2691-702.
    • (2006) J Exp Med , vol.203 , pp. 2691-2702
    • Serafini, P.1    Meckel, K.2    Kelso, M.3
  • 50
    • 68849128500 scopus 로고    scopus 로고
    • Therapeutic targeting of myeloid-derived suppressor cells
    • Ugel S, Delpozzo F, Desantis G, et al. Therapeutic targeting of myeloid-derived suppressor cells. Curr Opin Pharmacol 2009; 9: 470-81.
    • (2009) Curr Opin Pharmacol , vol.9 , pp. 470-481
    • Ugel, S.1    Delpozzo, F.2    Desantis, G.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.